V Janz1, J Löchel2, A Trampuz3, K-D Schaser4, A Hofer2, G I Wassilew2. 1. Klinik und Poliklinik für Orthopädie und Orthopädische Chirurgie, Universitätsmedizin Greifswald KöR, Sauerbruchstr., 17475, Greifswald, Deutschland. Viktor.Janz@med.uni-greifswald.de. 2. Klinik und Poliklinik für Orthopädie und Orthopädische Chirurgie, Universitätsmedizin Greifswald KöR, Sauerbruchstr., 17475, Greifswald, Deutschland. 3. Centrum für Muskuloskelettale Chirurgie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland. 4. Universitäts Centrum für Orthopädie & Unfallchirurgie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland.
Abstract
BACKGROUND: Periprosthetic joint infection (PJI) of megaprostheses occur in about 10% of all cases. The criteria for PJI are defined by the "Musculoskleletal Infection Society" (MSIS) and apply to both primary arthroplasty and megaprostheses. MANAGEMENT: The management strategies of PJI in megaprostheses are dependent on the duration of infection and the maturity of the bacterial biofilm. Implant retention with an exchange of the mobile components is only possible in the presence of an immature biofilm. In the presence of a mature biofilm, a one- or two-stage exchange must be performed. A complete exchange of all endoprosthetic components should be performed, if possible, since a partial retention of isolated components results in inferior treatment success rates. RESULTS: The highest success rates are achievable with two-stage exchanges. Multiple risk factors such as skin necrosis, postoperative haematoma, prolonged wound secretion and operative times ≥ 2.5 h are risk factors for the development of PJI in megaprostheses. Knowledge regarding these risk factors allows for an identification of high-risk patients and early management of PJI.
BACKGROUND: Periprosthetic joint infection (PJI) of megaprostheses occur in about 10% of all cases. The criteria for PJI are defined by the "Musculoskleletal Infection Society" (MSIS) and apply to both primary arthroplasty and megaprostheses. MANAGEMENT: The management strategies of PJI in megaprostheses are dependent on the duration of infection and the maturity of the bacterial biofilm. Implant retention with an exchange of the mobile components is only possible in the presence of an immature biofilm. In the presence of a mature biofilm, a one- or two-stage exchange must be performed. A complete exchange of all endoprosthetic components should be performed, if possible, since a partial retention of isolated components results in inferior treatment success rates. RESULTS: The highest success rates are achievable with two-stage exchanges. Multiple risk factors such as skin necrosis, postoperative haematoma, prolonged wound secretion and operative times ≥ 2.5 h are risk factors for the development of PJI in megaprostheses. Knowledge regarding these risk factors allows for an identification of high-risk patients and early management of PJI.
Entities:
Keywords:
Biofilm; Bone Cancer; Endoprosthesis; Prosthesis failure; Prosthesis-related infections
Authors: Eric R Henderson; John S Groundland; Elisa Pala; Jeremy A Dennis; Rebecca Wooten; David Cheong; Reinhard Windhager; Rainer I Kotz; Mario Mercuri; Philipp T Funovics; Francis J Hornicek; H Thomas Temple; Pietro Ruggieri; G Douglas Letson Journal: J Bone Joint Surg Am Date: 2011-03-02 Impact factor: 5.284
Authors: Philipp T Funovics; Christian Hipfl; Jochen G Hofstaetter; Stephan Puchner; Rainer I Kotz; Martin Dominkus Journal: Int Orthop Date: 2010-08-28 Impact factor: 3.075
Authors: Edward J McPherson; Chris Woodson; Paul Holtom; Nikolaos Roidis; Chrissandra Shufelt; Michael Patzakis Journal: Clin Orthop Relat Res Date: 2002-10 Impact factor: 4.176